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Evaluating effect of obesity per se and the metabolic syndrome as a whole on the risk of developing chronic
kidney disease (CKD) is key factor in developing a comprehensive public health approach to reduce morbidity and
healthcare resource consumption. While there is considerable evidence to support increased risk of CKD in obese
individuals and those with the metabolic syndrome, this relationship may be influenced by several factors. These
include confounding variables, anthropometric measures, the end-point studied (e.g. development of early stage
CKD, progression to end-stage renal disease or mortality), and the complex interrelationship between the various
components of the metabolic syndrome. The study by Cao et al. in the current issue of BMC nephrology examines the
impact of obesity on CKD risk in people with and without co-existing metabolic syndrome. The findings of this large,
prospective study illustrate a clear correlation between increased body mass index (BMI) and risk of CKD regardless of
whether or not there is co-existing metabolic syndrome. While the presence of the metabolic syndrome confers some
additional risk of CKD in overweight and obese individuals, its effect is relatively modest and accounts for only 26 % of
the risk associated with increased BMI. We discuss the complex epidemiological and methodological context in which
these important findings should be understood, and their implications for public health and for individual patients and
healthcare practitioners.Background
Identifying individuals at increased risk for chronic kid-
ney disease (CKD) is an important, yet difficult under-
taking. Its importance is related both to the high
prevalence of CKD [1], and to the profound effect that
its progression to end stage renal disease (ESRD) has on
mortality, morbidity, quality of life and healthcare re-
source consumption [2, 3]. Establishing the risk factors
and markers for CKD is key in developing a comprehen-
sive public health approach that may include screening,
patient education, life-style modifications, pharmaco-
therapy and other interventions to decrease CKD and
subsequent ESRD [4]. The difficulties in achieving this
goal, however, are formidable. CKD is a highly hetero-
geneous condition. Most people with CKD have mild,
asymptomatic, reductions in glomerular filtration rate
(GFR), or mild proteinuria, while a minority of patients at* Correspondence: lshavit@szmc.org.il
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ESRD, and suffer its heavy toll on their health and
well-being [4]. Therefore, the meaning of an associ-
ation between a given variable and CKD as a whole is
often unclear. For some conditions associated with
CKD, such as hypertension, distinguishing cause from
effect is often problematic. Finally, the complex, often
confounding, interrelationship and overlap among the
many risk factors that have been implicated as con-
tributing to the development of CKD can make it
quite hard to isolate independent risk factors [5]. The
case of metabolic syndrome and its components,
obesity, hyperglycemia, dyslipidemia, and hyperten-
sion, illustrates the murkiness in which the epidemio-
logical research of CKD risk must navigate.
Obesity and overweight may appear as straightforward,
easily studied, potential risk factors for CKD. Indeed,
compelling evidence has been found for an independent
association between BMI and CKD risk in healthy men
[6], and hypertensive adults [7]. One very large study ofle is distributed under the terms of the Creative Commons Attribution 4.0
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ing health check-ups between 1964 and 1985 found that
the long term risk of ESRD was strongly and independ-
ently associated with being overweight or obese, with an
odds ratio as high as 7 in extreme obesity (BMI>=40)
[8]. Other studies, however, found that the apparent as-
sociation of BMI with stage 3 CKD, was no longer sig-
nificant after adjustment for other cardiovascular risk
factors [5]. A study of patients who already had stage 3–5
CKD, showed no association between BMI and reduction
in eGFR [9]. Furthermore, the location of body fat, by an-
thropometric measures such as waist to hip ratio (WHR)
was found in some studies to be more important than
BMI per se in predicting CKD and mortality [10], whereas
others found waist circumference and BMI (but not
WHR) to be useful predictors of CKD risk [11]. In terms
of predicting ESRD and mortality in CKD patients, BMI
shows a relatively consistent U-shaped association with
clinical outcomes, with the best outcomes observed in
overweight and mildly obese patients, while low BMI is as-
sociated with worse outcomes in all patients, independent
of severity of CKD [12]. In contrast, a higher waist cir-
cumference was consistently associated with increased
mortality [13].
The examination of metabolic syndrome as a risk fac-
tor for CKD entails additional complexity. The very def-
inition of metabolic syndrome has eluded full consensus,
and even small variations in criteria may affect results in
studies of large patient cohorts. Even with efforts to-
wards a more widely accepted definition [14], there may
be considerable heterogeneity among patients since only
3 of 5 criteria need to be met, and, thus, different pa-
tients might be defined as having metabolic syndrome
based on different findings. Additionally, the clustering
of several risk factors into one variable may either mask
or artificially enhance associations between predictor
and outcome and make them more difficult to interpret.
Nevertheless, an association between the metabolic syn-
drome and an increased incidence of CKD appears to be
well supported by empirical data [15, 16].Main text
The article by Cao et al. in this issue of BMC nephrology
is a welcome addition to our knowledge and understand-
ing of this complex issue. It presents the results of a
large scale prospective observational cohort study asses-
sing the independent impact of obesity with or without
co-existing metabolic syndrome on the risk of new onset
CKD [17]. In view of the potentially modifiable nature of
obesity and at least some of the other components of
metabolic syndrome, information about the relative con-
tribution of each abnormality to the development of
CKD has potentially significant clinical implications.Cao et al. describe a cohort of 6852 Chinese individ-
uals from Changsha, central south China, who were pro-
spectively followed for an average of 54.3 months. The
cumulative incidence of new onset CKD (defined as de-
velopment of either eGFR < 60 mL/min/1.73 m2 or iso-
lated positive proteinuria during the follow up period) in
this cohort was recorded [17]. Overweight and obesity
was highly prevalent and found in more than 40 % of
the study patients. As expected, the incidence of meta-
bolic syndrome significantly and positively correlated
with increasing body mass.
Cao et al. showed that the cumulative incidence of
CKD increased stepwise with higher BMI category inde-
pendent of the presence or absence of metabolic syn-
drome. The hazard ratios for new onset CKD were 1.82
(95 % CI, 1.36-2.42) in overweight and 3.82 (95 % CI,
2.47-6.12) in obese individuals without metabolic syn-
drome when normal weight individuals without meta-
bolic syndrome were considered as a reference group.
More interestingly and similar to individuals without
metabolic syndrome, obesity was found to independently
increase the cumulative incidences of new onset CKD in
those with coexisting metabolic syndrome. The excess
risk mediated by metabolic syndrome in the association
between BMI (as a continuous variable) and CKD was
26 %. As higher BMI significantly and positively corre-
lated with metabolic syndrome, this finding means that
only 26 % of the CKD risk induced by BMI can be ex-
plained by associated metabolic syndrome. Not unex-
pectedly, the risk of CKD rose in stepwise fashion as the
number of components of the metabolic syndrome in-
creased, further emphasizing the complex interrelation-
ship between individual components of the syndrome
and their simultaneous contributions to the development
of CKD.
Thus, this well performed large-scale study shows in-
dependent and joint adverse associations between BMI
and incident CKD, whereas other metabolic parameters
have additive effects on this risk. Although interest in
the association between obesity, metabolic health and
CKD has been longstanding, several prior large scale stud-
ies have missed the critical point of stratification of the
analysis by the absence or presence of the metabolic syn-
drome and, therefore, did not answer the question
whether metabolic health modifies this association [6–8].
Thus, Cao et al. should be commended for evaluating this
clinically significant point. However, another recently pub-
lished prospective epidemiological study of 21,840 partici-
pants studied associations between obesity, metabolic
health, and the risk of end-stage renal disease (ESRD) and
yielded different results [18]. This study showed that the
metabolic syndrome, but not increased BMI, is a powerful
risk factor for ESRD. Moreover, higher BMI was asso-
ciated with lower risk of ESRD in those without the
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with ESRD risk was observed in those with the meta-
bolic syndrome. Certainly, these results have added
further complexity to our understanding of how obes-
ity, metabolic syndrome and CKD, might be associ-
ated. Profound differences in studied populations and
methodology can, at least partially, explain the dis-
crepancy between these studies. First, race and age
differences were prominent: Cao et al. evaluated
young Asian participants, whereas Panwar et al. fo-
cused on white and black participants who were sig-
nificantly older. Indeed, aging is associated with
considerable changes in body weight and more im-
portantly, composition [19]. Moreover, the relative
risk of adverse outcomes associated with obesity de-
creases with increasing age, and the BMI value associ-
ated with the lowest mortality is higher in older than
in younger adults [19]. Though no data evaluating
BMI as an independent risk factor for CKD in the
elderly exist to date, one would expect that aging can
modify the association of BMI with CKD. Addition-
ally, methodological variations can result in different
conclusions: Panwar et al. examined the independent
associations of BMI and metabolic health with risk of
ESRD, while Cao et al. evaluated these associations
with risk of early CKD. It is quite possible that in-
creased BMI can be an independent risk factor for
early CKD in patients with normal baseline kidney
function, but not for ESRD. Moreover, several previ-
ous studies have shown that higher BMI may be “pro-
tective” in patients with advanced stages of CKD and
associated with improved survival [12]. Although the
physiological mechanisms underlying this ‘obesity
paradox’ are not well understood, poor nutritional
status, protein energy wasting and inflammation,
which often coexist with lower BMI in advanced
CKD, are thought to be major underlying mechanisms
responsible for increased mortality in this population
[20]. Clearly, the effects of BMI and coexisting meta-
bolic parameters on the risk of development and pro-
gression of kidney disease are modified by several
important demographic and clinical factors; thus, crit-
ical analysis of current literature addressing this com-
plex subject is crucial for clinicians faced with the
uncertainty caused by the disparate results of different
clinical studies.
The study by Cao et al. [17] was not designed to eluci-
date mechanisms that may explain the nexus between
metabolic syndrome, obesity and risk of CKD. Deleteri-
ous effects of intraglomerular hypertension and glom-
erular hyperthrophy, increased secretion of transforming
growth factor beta (TGF-β) leading to glomerulosclero-
sis, hormonal changes, such as hyperaldosteronism and
related pro-inflammatory cytokine secretion, includinginterleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-α), coexisting lipid disorders and insulin resistance
have all been implicated in obesity-driven CKD [21].
There is no doubt that the complex pathophysiology of
all three disease states, metabolic syndrome, obesity and
risk of CKD, should be an active area of investigation by
the clinical and basic scientist alike, especially in light of
the potentially modifiable nature of obesity and other
metabolic parameters and its impact on patient outcome.
Obesity is associated with the development of multiple
medical conditions and comorbid illnesses, including cor-
onary artery disease, stroke, type II diabetes, CKD, prema-
ture death and reduced quality of life [5]. It is well
established that controlling obesity and the metabolic ab-
normalities are important to cardiovascular disease pre-
vention. However, very little is known about the effects of
weight reduction on CKD development and progression.
Although several animal and human studies point out
the positive effects of caloric restriction on albuminuria,
blood pressure and glomerular hyperfiltration, the effect
of weight reduction on hard renal outcomes is still un-
known [21]. Sedentary lifestyle, which is closely linked
with obesity and poor metabolic health, has been re-
cently evaluated in conjunction with CKD risk. The ex-
tent of a patient’s physical social network, defined as the
number of social interactions and personal relationships,
education, moderate alcohol intake, and physical activity
has been found to be significantly and independently as-
sociated with the incidence and progression of early
CKD among those with type 2 diabetes [22].
Conclusions
Modifiable lifestyle and social factors, which often over-
lap with overweight and obesity, can determine both kid-
ney and cardiac health in people at high cardiovascular
and renal risks. Despite the complexity in determining
independent associations between BMI, metabolic syn-
drome and incident CKD, clinicians should ensure that
patients with obesity and metabolic syndrome are
screened and appropriately managed for early CKD and
modifiable lifestyle risk factors, in order to reduce the
risk of both renal and cardiovascular morbidity.
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